Corcept Therapeutics (CORT) Research & Development (2016 - 2025)
Historic Research & Development for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $68.8 million.
- Corcept Therapeutics' Research & Development rose 1602.74% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.4 million, marking a year-over-year increase of 1256.37%. This contributed to the annual value of $246.9 million for FY2024, which is 3392.08% up from last year.
- As of Q3 2025, Corcept Therapeutics' Research & Development stood at $68.8 million, which was up 1602.74% from $60.5 million recorded in Q2 2025.
- Corcept Therapeutics' 5-year Research & Development high stood at $70.3 million for Q4 2024, and its period low was $28.1 million during Q3 2021.
- Its 5-year average for Research & Development is $45.6 million, with a median of $43.3 million in 2023.
- In the last 5 years, Corcept Therapeutics' Research & Development plummeted by 1705.98% in 2021 and then soared by 4884.64% in 2023.
- Quarter analysis of 5 years shows Corcept Therapeutics' Research & Development stood at $28.5 million in 2021, then grew by 28.88% to $36.8 million in 2022, then soared by 48.85% to $54.7 million in 2023, then increased by 28.5% to $70.3 million in 2024, then dropped by 2.07% to $68.8 million in 2025.
- Its Research & Development stands at $68.8 million for Q3 2025, versus $60.5 million for Q2 2025 and $60.7 million for Q1 2025.